People with relapsing remitting MS starting early treatment with a disease modifying drug have a lower risk of converting to secondary progressive MS, according to a study of medical records.
- Stem cells effective in aggressively relapsing MS
- Benefits of early DMD treatment
- Guidelines for MS treatment during pregnancy published
- Mindfulness helps mood and fatigue
An international study for people with highly active relapsing multiple sclerosis has reported that those having stem cell treatment had slower disability progression.
- Cooling helps with exercise
- Rituximab and SPMS
- Ocrevus and arm function in PPMS
- Plasma cells from gut can turn off brain inflammation
New guidelines for pregnancy care in multiple sclerosis, drawn up by a panel of UK experts including the MS Trust, have been published.
- Relapses more likely in people with food allergies
- Reducing Ocrevus injection site reactions
- Fampridine and walking speed
- SMC approves Ocrevus
- Australian stem cell study
- Switching interferons increases relapse risk
The Scottish Medicines Consortium (SMC) has approved Ocrevus (ocrelizumab) as an NHS treatment for relapsing remitting multiple sclerosis in Scotland.